MMJ BioPharma Cultivation finds itself at the center of a pivotal legal struggle with the Drug Enforcement Administration (DEA), accusing the agency of significant delays in processing its application to grow marijuana for pharmaceutical research. The company’s lawsuit claims these delays have hindered critical clinical trials aimed at developing treatments for debilitating conditions such as Multiple Sclerosis (MS) and Huntington’s Disease (HD), thereby prolonging the suffering of patients who could benefit from cannabis-based therapies. MMJ Struggles With DEA DelaysDuane Boise, president and…
